STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[6-K] BRIGHT MINDS BIOSCIENCES INC. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File No. 001-40997

BRIGHT MINDS BIOSCIENCES INC.
(Translation of registrant's name into English)

19 Vestry Street,
New York, NY  10013
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  [ X ]  Form 40-F [  ]


SUBMITTED HEREWITH

Exhibits  
99.1 News Release dated November 6, 2025


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  BRIGHT MINDS BIOSCIENCES INC.
   
  (signed) "Ryan Cheung"
  Ryan Cheung
  Chief Financial Officer

Date:  November 7, 2025


Bright Minds Biosciences Inc

NASDAQ:DRUG

DRUG Rankings

DRUG Latest News

DRUG Latest SEC Filings

DRUG Stock Data

397.74M
5.76M
22.42%
73.98%
2.79%
Biotechnology
Healthcare
Link
United States
New York